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We  evaluated  the humoral  and  cellular  immune  responses  in  pigs  immunized  intranasally
with crude  rhoptry  proteins  of  Toxoplasma  gondii  plus  Quil-A.  The  experiment  used  13
mixed-breed  pigs  divided  into  the  following  three  groups:  G1  (vaccinated-challenged,
n  = 6),  which  received  the  rhoptry  vaccine  (200  (g/dose);  G2  (adjuvant-challenged,  n  =  4),
which received  PBS  plus  Quil-A;  and  G3  (unvaccinated-challenged,  n  =  3), which  was  the
control group.  The  treatments  were  performed  intranasally  at  days  0, 21,  and  42. Three
pigs from  G1  produced  IgG and  IgM  antibody  levels  above  the  cut-off  in  the  ELISA onhoptry
ucosal  immunity
igs
the challenge  day.  Partial  protection  was  observed  in  G1  at  the  chronic  phase  of  infec-
tion  when  compared  with  G3.  The  preventable  fractions  were  41.6%  and 6.5%,  in  G1  and  G2,
respectively.  The  results  of this  study  suggest  that  rhoptry  proteins  plus  Quil-A  stimulated
humoral,  local,  and systemic  immune  responses,  which  were  able  to partially  protect  the
brain from  cyst  formation.. Introduction
Toxoplasma gondii is a protozoan parasite that can infect
umans and warm-blooded animals. Humans can become
nfected by ingesting raw or undercooked meat contain-
ng  cysts (Garcia, 2009). The longevity of a tissue cyst in
ork  can last more than two years (Dubey et al., 1998), and
ork  is one of the most common sources of T. gondii infec-
ions  in humans (Dubey et al., 1991). These results indicate
hat  developing a vaccine against T. gondii in pigs would be
esirable  to reduce tissue cyst formation.
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Live vaccines (RH, T263, and S48) have shown protec-
tion against toxoplasmosis (Frenkel et al., 1991; Dubey
et  al., 1991, 1994), but these carry the risk of reverting to
virulence (Supply et al., 1999). A useful T. gondii vaccine
for  human beings and animals needs to be safe (non-
infectious), to have a reasonable shelf life, to be usable in
pregnant  females without infecting the fetuses, to protect
against transplacental infection, and to avoid oocyst shed-
ding  by cats and tissue cyst formation in animals (Garcia,
2009).
A  vaccine study using crude T. gondii antigens incor-
porated into ISCOM subcutaneously in pigs, monitored
Open access under the Elsevier OA license.through a mouse bioassay, did not isolate tissue cysts from
vaccinated animals (Freire et al., 2003). Garcia et al. (2005)
used  rhoptry proteins incorporated into ISCOM to prevent
tissue  cyst formation in pigs challenged with sporulated
ry ParasI.A.L.d. Cunha et al. / Veterina
oocysts of the VEG strain. The results indicated that the
rhoptry vaccine conferred partial protection during the
chronic phase of the disease.
Smith et al. (1998) showed that oral administration of
free Quil-A together with OVA reproduced most of the local
and systemic immune responses obtained with ISCOM and
OVA. The saponin adjuvant Quil-A is obtained from the bark
of a tree, Quillaja saponaria.  Quil-A is a widely used vet-
erinary adjuvant that is inexpensive, simple to formulate,
and generally safe (Cox and Coulter, 1997). Additionally,
QS21, a puriﬁed fraction from Quil-A, was used for con-
trol of Plasmodium falciparum in humans, and the authors
described an enhanced in immunogenicity of peptide vac-
cine (Kashala et al., 2002).
The most common infection route of T. gondii is oral
ingestion. Therefore, stimulation of a mucosal immune
response will be desirable in controlling oral toxoplas-
mosis (Chardés and Bout, 1993). The intranasal route has
been evaluated as an immunization route in pigs, however,
these studies tested virus and bacterial immune responses
(Yokomizo et al., 2002; Zhang et al., 2007; Neumann
et al., 2009). Yokomizo et al. (2002) showed that intranasal
immunization is more efﬁcient for inducing local and sys-
temic immunity than oral immunization in pigs.
In the present study, we evaluated humoral and cellu-
lar immune responses in pigs immunized intranasally with
crude rhoptry proteins of T. gondii plus Quil-A.
2. Materials and methods
2.1. Toxoplasma gondii strain
LIV-5 and VEG T. gondii strains were used in the exper-
iment. LIV-5 strain was used to obtain rhoptries and VEG
strain was used for the pigs challenge. Oocysts from VEG
strain were obtained from feces of recently infected cats.
After sporulation the oocysts had their virulence tested by
mouse infection before pig infection.
2.2. Rhoptries puriﬁcation
Tachyzoites of LIV-5 strain were obtained from peri-
toneal ﬂuid of infected Swiss mice. The material was passed
three times through a 26 gauge needle to puriﬁcation
and washed twice with 10 mM phosphate buffered saline
(PBS, pH 7.5). The pellet was resuspended and washed
twice in homogenization medium (HM: 250 mM sucrose;
1 mM EDTA; 5 mM triethanolamine–HCl; pH 7.5), after
washed, tachyzoites were prepared at a concentration of
109 tachyzoites/mL. Cell suspension was disrupted in a
French pressure cell at 50 kg/cm3. Unbroken cells were sed-
imented by a 10 min  centrifugation at 750 × g. Supernatant
was centrifuged at 12,000 × g for 10 min  to sediment the
crude organellar. Final pellet was fractionated by isopy-
nic sucrose density gradient centrifugation to rhoptries
isolation following Garcia et al. (2004).  Brieﬂy, the ﬁnal
pellet was resuspended in 4 mL  of HM,  layered onto a
6 mL  preformed continuous 1.0–1.6 M sucrose gradient and
centrifuged overnight at 72,000 × g. Sub-fractions were
collected from each visible gradient fraction, suspended in
10 mL  of HM,  and pelleted by centrifugation 120,000 × gitology 186 (2012) 216– 221 217
for 1 h. Fraction 3 (1.4 M and a density of 1.17 g/cm3)
showed rhoptries (Garcia et al., 2004) and was used to vac-
cinated the animals. From one hundred mice infected with
T. gondii LIV-5 we  collected 300 mL  of peritoneal ﬂuid with
3 × 107 tachyzoites/mL and obtained 4600 g of rhoptry
proteins in a total volume of 2 mL.  Protein concentration in
each sub-fraction was determined using the bicinchoninic
acid technique (BCA Protein Assay Reagent, Pierce).
2.3. Vaccination and challenge of pigs
2.3.1. Animals
The maintenance and care of experimental animals
complied with the Animal Ethic Committee from Uni-
versidade Estadual de Londrina (CEEA 17/09). Thirteen
mixed breed pigs between 6.5- and 7.5-week-old, includ-
ing females and castrated males, were randomly allocated
in separate stables (2 for 2). The animals were left to accli-
matize for 6 days before we began the experiment. They
received food and water ad libitum. All pigs were serum
negative (titre < 64) in the T. gondii indirect immunoﬂuo-
rescence assay (IFA).
2.3.2. Vaccination and challenge
The pigs were divided into 3 groups, group 1 (G1, n = 6),
group 2 (G2, n = 4) and group 3 (G3, n = 3). The G1 received
200 g of rhoptry proteins plus Quil-A (50 g) by nasal
route (NA) at days 0, 21, and 42 of the experiment. The
G2 and G3 received just Quil-A (50 g) and PBS by nasal
route, respectively. At challenge day (day 49) two animals
from G1 were euthanatized for lymphocytes proliferation
assay, and the other animals from G1 (n = 4), G2 (n = 4) and
G3 (n = 3) were challenged with 103 oocysts of VEG strain
by oral route.
2.3.3. Sampling and measurements
Clinical signs and body temperatures were recovered
before and after challenge. Serum samples were obtained
at days −6, 0, 21, 42, 49, 64, 79 and at slaughter (day 94) and
stored at −20 ◦C. At death, brain samples were collected to
investigate T. gondii tissue cysts by mouse bioassay.
2.3.4. Immunoﬂuorescence assay (IFA)
The presence of antibodies against T. gondii in serum
samples of pigs (before of experiment to select the animals)
and mice were measured by indirect immunoﬂuorescence
assay (Camargo, 1974) considering as positive pigs with
titre ≥ 64 and mice with titre ≥ 16 (Garcia et al., 2005).
2.4. Enzyme-linked immunosorbent assay (ELISA) for
IgG, and IgM
Flat-bottom 96 well polystyrene microtitration plates
(Nunc-Immuno Plate, MaxiSorp, Denmark) were coated
with 0.1 mL  of the rhoptry antigens (5 g/well) diluted in
0.1 M carbonate buffer (pH 9.6) and incubated overnight at
+6 ◦C as described by Garcia et al. (2005).  The plates were
washed 3 times with PBS-tween 20 (50 mM tris, pH 7.4,
containing 150 mM sodium chloride and 0.05% tween 20)
and non-speciﬁc immune sites blocked by incubation for
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 h at 37 ◦C with carbonate buffer −8% nonfat dry milk.
he control sera and test sera were diluted 1:200 in PBS-
ween 20–5% nonfat dry milk and added to the microtitre
lates in duplicate, 0.1 mL  in each well, and incubated for
 h at 37 ◦C. The positive and negative control sera were
ncluded in each plate. After washing, peroxidase-labeled
nti-pig IgG and IgM antibody (Bethyl Laboratories Inc.,
iluted 1:2500 in PBS-tween 20–5% nonfat dry milk) was
dded 0.1 mL  in each well and incubated for 1 h at 37 ◦C.
fter washing, the peroxidase activity was revealed by
dding 0.1 mL  of ortho-phenylenediamine solution (40 mg
rtho-phenylenediamine/100 mL  of 0.1 M phosphate cit-
ate buffer, pH 6.0, and 40 L of H2O2), and the reaction
as stopped by adding 0.05 mL  of 1 N HCL, and the optical
ensity (OD) was read at 490 nm in an ELISA microplate
eader. For control of plate-to-plate variation, the same
ositive and negative control sera were included on every
late and a corrected OD value was calculated for each
ample as described previously by Garcia et al. (2006).
 serum was considered to be positive when OD testes
erum > [OD mean (from negative sera obtained from all
lates, n = 15) + 2 SD (standard deviation from negative
erum from all plates)].
.5. Lymphocyte proliferation
The proliferation assays of peripheral blood mononu-
lear cells (PBMC) and lymphocytes from mesenteric
ymph nodes (LMLN) were performed as previously
escribed (Solano-Aguilar et al., 2000). Two pigs from
1 were euthanized at challenge day. Whole blood was
btained by venipuncture in EDTA vacutainers and mixed
:2 with phosphate-buffered saline (PBS), and MLN  were
ollected from ileum and jejunum into 50-mL conical
ubes and kept in collection media (CM) at 4 ◦C. Cells
rom MLN  were release by sharp scissors into a petri
ish containing RPMI 1640 medium (GIBCO), and then
he cell suspension were ﬁltered. PBMC were isolated by
ensity gradient centrifugation by using lymphocyte sepa-
ation media (LSM). The isolated cells were washed twice
n RPMI 1640 medium. The cell suspensions from PBMC
nd MLN  were cultured in RPMI 1640 medium (GIBCO)
upplemented with 10% bovine fetal serum, l-glutamine
2 mM;  BioWhittaker), sodium pyruvate (1 mM;  Sigma),
nd penicillin–streptomycin (1 mM;  Sigma). The suspen-
ions were then seeded in triplicate at 106 cells per well
nto ﬂat-bottomed 96-well microtiter plates (Costar) with
00 L of culture medium that contained 5, 10, and 15 g
f rhoptry proteins per mL.  Phytohemagglutinin-M (Sigma)
t 10 g/per mL  was then added to the culture medium
nd served as positive control for proliferation; while
edium without additives were used as the negative con-
rols. The plates were incubated in 5% CO2 at 37 ◦C for 64 h.
he viability of the cells was higher than 90% as deter-
ined by trypan blue exclusion. The cellular proliferation
as determined by Vybrant MTT  Cell Proliferation Assay
it (Molecular Probes). The absorbance determination at
70 nm was realized by using a microplate reader; prolif-
ration was expressed as stimulation indices (SI = ratio of
he mean proliferation of the cells after stimulation relativeitology 186 (2012) 216– 221
to the proliferation of unstimulated control cells from the
same animal).
2.6. Bioassay of pig brains for T. gondii
Brain samples (50 g) from each pig were used to evalu-
ate the presence of T. gondii cysts as described previously
(Dubey, 1998). Brieﬂy, each sample was homogenized in a
blender for 30 s in 250 mL of saline solution (0.14 M NaCl).
After homogenization 250 mL  of pepsin solution (50 g) was
added and incubated at 37 ◦C for 1 h. The homogenate
was  ﬁltered through 2 layers gauze and centrifuged at
1180 × g for 10 min. The supernatant was discarded and
the sediment was  resuspended in 20 mL  PBS (pH 7.2) and
15 mL  1.2% sodium bicarbonate (pH 8.3) was  added and
centrifuged at 1180 × g for 10 min. The supernatant was
discarded and the sediment was  resuspended in 5 mL  of
antibiotic saline solution (1000 U penicillin and 100 L of
streptomycin/mL of saline solution) and inoculated subcu-
taneously into 3 mice (1 mL/mouse).
2.7. Examination of mice
Impression smears of lung from the mice that died were
ﬁxed in methanol, stained with Giemsa, and examined
microscopically. Blood samples were drawn from the mice
that survived 45 days after post-inoculation, and the brain
of each mouse was  examined microscopically for T. gondii
tissue cysts by squashing a portion of brain between a cov-
erslip and a glass slide. Serum from each mouse was  diluted
at 1:16 and 1:64 and examined for T. gondii antibodies,
using IFA.
2.8. Statistical analyses
Qui-square was  used to show statistical difference in
mice bioassay. Protection against tissue cysts formation
in pigs was evaluated by estimating preventable fraction
(PF) as previously described (Siev, 1994) with some adjust-
ments; PF = (p2 − p1)/p2, where p2 = % of positive mice from
pigs from G3 and p1 = % of positive mice from pigs from G1
or G2. The statistical evaluation of the lymphocyte prolif-
eration data was performed using the Student’s t-test.
3. Results
There were no clinical symptoms of toxoplasmosis in
pigs after the challenge (ac), except for a fever on days
6–8 ac (>40.0 ◦C, Fig. 1).
IgG and IgM antibody results are shown in Fig. 2. The
average antibody levels at the challenge in the immunized
group (G1) were IgG OD mean = 0.222 ± 0.229 and IgM OD
mean = 0.445 ± 0.215. Three animals from G1 had IgG and
IgM antibody levels above the cut-off on the challenge day
(ODIgG = 0.195, IgM OD mean = 0.376). Animals from G2
and G3 remained IgG and IgM negative before the chal-
lenge. All pigs from G1, G2, and G3 seroconverted after
the challenge. The IgM antibody levels had a downward
tendency after the challenge day, and some animals were
negative.
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Fig. 3. Lymphocyte proliferation response from peripheral blood
mononuclear cells (PBMCs) and mesenteric lymph nodes (MLNs) from
G1  (two animals) at challenge day (day 49). The lymphocyte stimulationare expressed as mean ± SEM. On the day 0 (day 49 of the experiment) all
animals were challenged (black arrow) with 103 oocysts of the T. gondii
VEG strain.
The proliferation assays of lymphocytes from peripheral
blood mononuclear cells (PBMCs), and mesenteric lymph
nodes (LMLNs) elicited lymphocyte proliferation response
(Fig. 3), however, the proliferation was higher in LMLNs
than PBMCs.
The results of the bioassay are summarized in Table 1.
Mouse bioassays of pig brains in G1, G2, and G3 animals
were positive: 5/11 (45.4%), 8/11 (72.7%), and 7/9 (77.8%).
The preventable fraction (PF) was 41.6% and 6.5% in G1 and
G2, respectively. One pig from G1 did not have brain cysts
detected through the mouse bioassay; however, all pigs
from G2 and G3 did have brain cysts.
4. Discussion
In the present study, we observed that intranasal immu-
nization with rhoptry proteins of T. gondii did not stimulate
all pigs to produce serum IgG and IgM antibodies, however,
the animals from G1 showed a partial protection against
tissue cyst burden. This is a particularly signiﬁcant ﬁnd-
ing, as it indicates that subunit vaccine for T. gondii could
be differentiated from natural infection (Garcia, 2009). This
could be important for future vaccination protocol for pre-
vent T. gondii in negative dams, including pregnant women.
Additionally, the lack of correlation between circulating
antibodies and intestinal immunity was described previ-
ously (Dubey and Frenkel, 1972). Frenkel and Smith (1982)
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Fig. 2. IgG and IgM antibody responses measure by the indirect enzyme-linked 
mean  from animals, and error bars = standard deviation). The G1 was vaccinated w
only  saline. The treatments were performed by nasal route at days 0, 21 and 42 (
oocysts of the T. gondii VEG strain (dashed arrow) and at day 94 all animals werewas  performed using 5, 10 and 15 g of T. gondii rhoptries and the positive
control stimulated with 1% of Phitohemaglutinin (PHA-M).
observed that immunity in the absence of antibodies was
reached, especially in cats treated with monesin (2/7) and
sulfadiazine (3/4), and the central focus of immunity to
oocyst shedding appears to be intestinal epithelium of kit-
tens (Frenkel et al., 1991).
Herein, lymphocyte responses were observed in the
blood and intestine of pigs (G1), but the proliferation was
higher in LMLNs than PBMCs. This could explain why G1
animals showed a higher PF (41.6%) than did G2 animals
(6.4%), including one G1 animal that did not show brain
cysts. Pork is considered the most common infection source
of T. gondii for human beings in the USA (Dubey, 2009);
therefore, a T. gondii vaccine for pigs should prohibit the
formation of tissue cysts (Garcia, 2009). Most of studies
about the immune response to T. gondii were done in
murine models, however, studies using pigs as T. gondii
model are important because there are some differences
IgM Rhoptry ELISA
0 21 42 49 64 79 94
G1
G2
G3
Experimental Days
immunosorbent assay (ELISA) from pigs of the G1, G2 and G3 (bars = OD
ith T. gondii rhoptry vaccine, G2 received PBS plus Quil-A, and G3 received
black arrows). At day 49 all groups received a challenge route of the 103
 slaughtered. Dashed line indicates positive cut-off.
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Table 1
Outcome of Toxoplasma gondii mouse bioassay performed from pig brains after treatments and challenged with oocysts of VEG strain.
Group/pig no. Sexa Immunization PIDb Challenge PID Bioassay of brain PID
0 21 42 49 Resultsd Pig negative (%)/mice negative
(%)/PF (%)e
94
G1
1 M Rhoptry (200 g) 0(1)/3
25/54.5/41.6
2 F + 103 oocysts 2/2g
3 F Quil-A (50 g) VEG 0(0)/3
4 M NAc 2(0)/3
G2
5  F 3/3
0/27.2/6.5
6  F Quil-A (50 g) 103 oocysts 0(1)/3
7  F NA VEG 0(2)/3
8  M 2/2g
G3
9 F
Saline
NA
103 oocysts
VEG
0(2)/3
0/22.2/NEf10 F 3/3
11 F  0(2)/3
a M:  male; F: female.
b PID: post inoculation day.
c NA: nasal route.
d Results are expressed as number of mice positive for T. gondii from three mice inoculated with pig brains. Numbers in parenthesis indicate the number
of  mice with antibody titers 16 (IFA), but in which tachyzoites or cysts were not seen in their lung, peritoneal liquid, and brain, respectively; tachyzoites
or  tissue cysts were seen in the other mice.
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Je Preventable fraction (PF) was  calculated from each group.
f Not evaluated.
g One mice died due to bacterial contamination.
n susceptibility, and immune mechanisms when compare
o mice (Dawson et al., 2005).
Clinical signs after T. gondii infection in pigs depend
n the breed and age of the animals, stage of the para-
ite, method of administration of parasite, and the number
f infective parasites (Jungersen et al., 1999). No clinical
ymptoms were observed, except for a rise in temperature
ccurring 5–8 days after challenge. Using the same strain
VEG) and number of oocysts to infect swine, Solano Aguilar
t al. (2001) observed death caused by severe ﬁbronecrotic
nteritis in 3 animals 10, 11, and 12 days after infection,
owever, these authors used miniature swine.
More recently, pigs were immunized intradermally
ith a DNA vaccine cocktail that encodes GRA1 and GRA7
ense granule proteins (Jongert et al., 2008). The authors
ound that this vaccine was able to elicit strong humoral
nd Type 1 cellular immune responses in those animals.
he results evaluating tissue cyst showed that two  out of
hree pigs vaccinated did not have the parasite detected in
eart.
In conclusion, we observed that nasal immunization
ith crude rhoptry proteins of T. gondii in pigs, using Quil-
 as an adjuvant, was able to stimulate a strong response
n LMLNs and partially protect animals from brain cyst for-
ation.
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